Loading...

Caryn Lerman

Title(s)Professor of Psychiatry & the Behavioral Sciences
Phone+1 323 865 0816
vCardDownload vCard
    Other Positions
    Title(s)H. Leslie Hoffman and Elaine S. Hoffman Chair in Cancer Research

    Title(s)Director, USC Norris Comprehensive Cancer Center


    Collapse Overview 
    Collapse Overview
    Dr. Lerman is the H. Leslie and Elaine S. Hoffman Professor in Cancer Research and Director of the USC Norris Comprehensive Cancer Center. Previously, she served as the John H. Glick Professor for Cancer Research and Vice Dean for Strategic Initiatives in the Perelman School of Medicine at the University of Pennsylvania. Prior to her Vice Dean appointment, she served as Senior Deputy Director of the Abramson Cancer Center for 10 years.

    Dr. Lerman is nationally recognized for her cancer prevention research that bridges the fields of neuroscience, pharmacology, genetics and behavioral science. She produced the first empirical data on the outcomes of genetic testing for cancer susceptibility, and was among the first to publish evidence for the genetic basis of cancer risk behaviors. Her pioneering work identifying genetic influences on tobacco use culminated in the first prospective stratified pharmacogenomic trial in the field of tobacco dependence, which has had a considerable impact on the application of precision medicine for tobacco dependence treatment. Supported by her National Cancer Institute (NCI) Outstanding Investigator Award (R35), Dr. Lerman now also leads a highly novel research program that harnesses advances in cognitive neuroscience to promote cancer risk behavior change. She has published over 380 peer reviewed publications, which have been cited over >20,000 times.

    An elected member of the National Academy of Medicine, Dr. Lerman has served as a member of the NCI Board of Scientific Advisors, the National Human Genome Research Advisory Council, and the National Institutes on Drug Abuse Advisory Council. She is also past president of the Society for Research on Nicotine and Tobacco.

    Collapse Research 
    Collapse Research Activities and Funding
    Neural basis of smoking relapse
    NIH/NIDA R01DA041402Apr 1, 2016 - Jan 31, 2021
    Role: Principal Investigator
    Neuroscience-based Interventions for Cancer Risk Behavior Change
    NIH/NCI R35CA197461Aug 1, 2015 - Jul 31, 2022
    Role: Principal Investigator
    UPENN TCORS: Tobacco Product Messaging in a Complex Communication Environment
    NIH/NCI P50CA179546Sep 18, 2013 - Aug 31, 2018
    Role: Co-Principal Investigator
    Retraining Neurocognitive Mechanisms of Cancer Risk Behavior (PQ4)
    NIH/NCI R01CA170297Sep 1, 2012 - Jun 30, 2016
    Role: Principal Investigator
    Cognitive Training for Nicotine Dependence
    NIH/NIDA R01DA030819Sep 30, 2010 - Jun 30, 2015
    Role: Principal Investigator
    Abramson Cancer Center Support Grant
    NIH/NCI P30CA147859Sep 30, 2009 - Sep 29, 2012
    Role: Principal Investigator
    Functional Characterization of OPRM1 A118G in Nicotine Dependence
    NIH/NIDA R21DA027066Sep 30, 2009 - Aug 31, 2011
    Role: Co-Principal Investigator
    Nicotine Abstinence-Induced Cognitive Alterations by COMT Genotype
    NIH/NIDA R03DA027438Sep 15, 2009 - Aug 31, 2012
    Role: Principal Investigator
    Center for Interdisciplinary Research on Nicotine Addiction (CIRNA)
    NIH/NCI P50CA143187Aug 1, 2009 - Jul 31, 2014
    Role: Principal Investigator
    Neural Substrates of Cognitive Deficits in Nicotine Withdrawal
    NIH/NIDA R01DA026849Aug 1, 2009 - May 31, 2013
    Role: Principal Investigator
    Pharmacogenetics of Nicotine Addiction Treatment
    NIH/NIDA U01DA020830Sep 15, 2005 - Jun 30, 2015
    Role: Principal Investigator
    Pharmacogenetic Investigation of Naltrexone
    NIH/NIDA R01DA017555Sep 30, 2003 - Jun 30, 2009
    Role: Principal Investigator
    Transdisciplinary Tobacco Use Research Centers
    NIH/NCI P50CA084718Sep 30, 1999 - Sep 29, 2009
    Role: Principal Investigator
    CANCER GENETICS NETWORK
    NIH/NCI U24CA078146Aug 1, 1998 - Sep 30, 2007
    Role: Co-Principal Investigator
    Decisions &Outcomes of BRCA1/2 Test for Breast Patients
    NIH/NCI R01CA074861Aug 1, 1997 - Jun 30, 2010
    Role: Co-Principal Investigator
    COMPARING MODELS OF COUNSELING FOR BRCA1/2 TESTING
    NIH/NHGRI R01HG001846Sep 30, 1994 - Aug 31, 2002
    Role: Co-Principal Investigator
    COMPARING MODELS OF PRETEST EDUCATION FOR BRCA1 TESTING
    NIH/NIMH R01MH054435Sep 30, 1994 - Aug 31, 1998
    Role: Principal Investigator
    COUNSELING WOMEN AT RISK FOR BREAST CANCER
    NIH/NCI R01CA063605Sep 30, 1993 - Jul 31, 1998
    Role: Principal Investigator
    BIOBEHAVIORAL LUNG CANCER PREVENTION PROGRAM
    NIH/NCI R01CA063562Sep 10, 1993 - May 31, 2004
    Role: Principal Investigator
    IMPROVING ADHERENCE IN WOMEN AT RISK FOR BREAST CANCER
    NIH/NCI R01CA057767Sep 30, 1992 - Feb 28, 1998
    Role: Principal Investigator
    PREVENTIVE ONCOLOGY ACADEMIC AWARD
    NIH/NCI K07CA001604Jul 1, 1991 - Jun 30, 1996
    Role: Principal Investigator
    USC Norris Comprehensive Cancer Center (Core) Grant
    NIH/NCI P30CA014089Apr 1, 1980 - Nov 30, 2020
    Role: Co-Principal Investigator
    Abramson Cancer Center Support Grant
    NIH/NCI P30CA016520Dec 1, 1978 - Nov 30, 2020
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Peng AR, Swardfager W, Benowitz NL, Ahluwalia JS, Lerman C, Nollen NL, Tyndale RF. Impact of Early Nausea on Varenicline Adherence and Smoking Cessation. Addiction. 2019 Sep 10. PMID: 31502736.
      View in: PubMed
    2. Chen J, Loukola A, Gillespie NA, Peterson R, Jia P, Riley B, Maes H, Dick DM, Kendler KS, Damaj MI, Miles MF, Zhao Z, Li MD, Vink JM, Minica CC, Willemsen G, Boomsma DI, Qaiser B, Madden PAF, Korhonen T, Jousilahti P, Hällfors J, Gelernter J, Kranzler HR, Sherva R, Farrer L, Maher B, Vanyukov M, Taylor M, Ware JJ, Munafò MR, Lutz SM, Hokanson JE, Gu F, Landi MT, Caporaso NE, Hancock DB, Gaddis NC, Baker TB, Bierut LJ, Johnson EO, Chenoweth M, Lerman C, Tyndale R, Kaprio J, Chen X. Genome-Wide Meta-Analyses of FTND and TTFC Phenotypes. Nicotine Tob Res. 2019 Jul 11. PMID: 31294817.
      View in: PubMed
    3. Ashare RL, Thompson M, Leone F, Metzger D, Gross R, Mounzer K, Tyndale RF, Lerman C, Mahoney MC, Cinciripini P, George TP, Collman RG, Schnoll R. Differences in the rate of nicotine metabolism among smokers with and without HIV. AIDS. 2019 May 01; 33(6):1083-1088. PMID: 30946162.
      View in: PubMed
    4. El-Boraie A, Taghavi T, Chenoweth MJ, Fukunaga K, Mushiroda T, Kubo M, Lerman C, Nollen NL, Benowitz NL, Tyndale RF. Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. Addict Biol. 2019 Feb 27. PMID: 30815984.
      View in: PubMed
    5. Robinson JD, Li L, Chen M, Lerman C, Tyndale RF, Schnoll RA, Hawk LW, George TP, Benowitz NL, Cinciripini PM. Evaluating the temporal relationships between withdrawal symptoms and smoking relapse. Psychol Addict Behav. 2019 Mar; 33(2):105-116. PMID: 30614717.
      View in: PubMed
    6. Falcone M, Bernardo L, Wileyto EP, Allenby C, Burke AM, Hamilton R, Cristancho M, Ashare RL, Loughead J, Lerman C. Lack of effect of transcranial direct current stimulation (tDCS) on short-term smoking cessation: Results of a randomized, sham-controlled clinical trial. Drug Alcohol Depend. 2019 01 01; 194:244-251. PMID: 30497056.
      View in: PubMed
    7. Mercincavage M, Lochbuehler K, Wileyto EP, Benowitz NL, Tyndale RF, Lerman C, Strasser AA. Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers: A Nonrandomized Clinical Trial. JAMA Netw Open. 2018 08; 1(4):e181346. PMID: 30627706.
      View in: PubMed
    8. Peng AR, Schnoll R, Hawk LW, Cinciripini P, George TP, Lerman C, Tyndale RF. Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes. Drug Alcohol Depend. 2018 09 01; 190:72-81. PMID: 29986268.
      View in: PubMed
    9. Taghavi T, Novalen M, Lerman C, George TP, Tyndale RF. A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine. Cancer Epidemiol Biomarkers Prev. 2018 08; 27(8):882-891. PMID: 29853480.
      View in: PubMed
    10. Tanner JA, Zhu AZ, Claw KG, Prasad B, Korchina V, Hu J, Doddapaneni H, Muzny DM, Schuetz EG, Lerman C, Thummel KE, Scherer SE, Tyndale RF. Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. Pharmacogenet Genomics. 2018 Jan; 28(1):7-16. PMID: 29232328.
      View in: PubMed
    11. Peng AR, Le Foll B, Morales M, Lerman C, Schnoll R, Tyndale RF. Improvement of the association between self-reported pill count and varenicline levels following exclusion of participants with misreported pill count: A commentary on Peng et al. (2017). Addict Behav. 2018 04; 79:14-16. PMID: 29232593.
      View in: PubMed
    12. Chenoweth MJ, Ware JJ, Zhu AZX, Cole CB, Cox LS, Nollen N, Ahluwalia JS, Benowitz NL, Schnoll RA, Hawk LW, Cinciripini PM, George TP, Lerman C, Knight J, Tyndale RF. Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. Addiction. 2018 03; 113(3):509-523. PMID: 28921760.
      View in: PubMed
    13. Peng AR, Morales M, Wileyto EP, Hawk LW, Cinciripini P, George TP, Benowitz NL, Nollen NL, Lerman C, Tyndale RF, Schnoll R. Measures and predictors of varenicline adherence in the treatment of nicotine dependence. Addict Behav. 2017 12; 75:122-129. PMID: 28728040.
      View in: PubMed
    14. Loughead J, Falcone M, Wileyto EP, Albelda B, Audrain-McGovern J, Cao W, Kurtz MM, Gur RC, Lerman C. Can brain games help smokers quit?: Results of a randomized clinical trial. Drug Alcohol Depend. 2016 Nov 01; 168:112-118. PMID: 27635998.
      View in: PubMed
    15. Rabin RA, Ashare RL, Schnoll RA, Cinciripini PM, Hawk LW, Lerman C, Tyndale RF, George TP. Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trial. Am J Addict. 2016 06; 25(4):291-6. PMID: 27187893.
      View in: PubMed
    16. Ross KC, Gubner NR, Tyndale RF, Hawk LW, Lerman C, George TP, Cinciripini P, Schnoll RA, Benowitz NL. Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. Pharmacol Biochem Behav. 2016 09; 148:1-7. PMID: 27180107.
      View in: PubMed
    17. Ashare RL, Lerman C, Cao W, Falcone M, Bernardo L, Ruparel K, Hopson R, Gur R, Pruessner JC, Loughead J. Nicotine withdrawal alters neural responses to psychosocial stress. Psychopharmacology (Berl). 2016 07; 233(13):2459-67. PMID: 27087432.
      View in: PubMed
    18. Ashare RL, Lerman C, Tyndale RF, Hawk LW, George TP, Cinciripini P, Schnoll RA. Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment? J Smok Cessat. 2017 Jun; 12(2):63-70. PMID: 28553407.
      View in: PubMed
    19. Allenby CE, Boylan KA, Lerman C, Falcone M. Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. J Neuroimmune Pharmacol. 2016 09; 11(3):471-83. PMID: 26872457.
      View in: PubMed
    20. Falcone M, Lee B, Lerman C, Blendy JA. Translational Research on Nicotine Dependence. Curr Top Behav Neurosci. 2016; 28:121-50. PMID: 26873019.
      View in: PubMed
    21. Falcone M, Cao W, Bernardo L, Tyndale RF, Loughead J, Lerman C. Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate. Biol Psychiatry. 2016 08 01; 80(3):190-7. PMID: 26805583.
      View in: PubMed
    22. Webb A, Papp AC, Curtis A, Newman LC, Pietrzak M, Seweryn M, Handelman SK, Rempala GA, Wang D, Graziosa E, Tyndale RF, Lerman C, Kelsoe JR, Mash DC, Sadee W. RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. BMC Genomics. 2015 Nov 23; 16:990. PMID: 26597164.
      View in: PubMed
    23. Falcone M, Bernardo L, Ashare RL, Hamilton R, Faseyitan O, McKee SA, Loughead J, Lerman C. Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking. Brain Stimul. 2016 Mar-Apr; 9(2):191-6. PMID: 26572280.
      View in: PubMed
    24. Dubroff JG, Doot RK, Falcone M, Schnoll RA, Ray R, Tyndale RF, Brody AL, Hou C, Schmitz A, Lerman C. Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. J Nucl Med. 2015 Nov; 56(11):1724-9. PMID: 26272810.
      View in: PubMed
    25. Bergen AW, Michel M, Nishita D, Krasnow R, Javitz HS, Conneely KN, Lessov-Schlaggar CN, Hops H, Zhu AZ, Baurley JW, McClure JB, Hall SM, Baker TB, Conti DV, Benowitz NL, Lerman C, Tyndale RF, Swan GE. Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. PLoS One. 2015; 10(7):e0126113. PMID: 26132489.
      View in: PubMed
    26. Chenoweth MJ, Schnoll RA, Novalen M, Hawk LW, George TP, Cinciripini PM, Lerman C, Tyndale RF. The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. Nicotine Tob Res. 2016 Apr; 18(4):491-5. PMID: 26069034.
      View in: PubMed
    27. Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW, Schnoll RA, Swan GE, Benowitz NL, Heitjan DF, Lerman C. Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. PLoS One. 2015; 10(5):e0128109. PMID: 26010901.
      View in: PubMed
    28. Tanner JA, Novalen M, Jatlow P, Huestis MA, Murphy SE, Kaprio J, Kankaanpää A, Galanti L, Stefan C, George TP, Benowitz NL, Lerman C, Tyndale RF. Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1239-46. PMID: 26014804.
      View in: PubMed
    29. Perkins KA, Karelitz JL, Michael VC, Fromuth M, Conklin CA, Chengappa KN, Hope C, Lerman C. Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. Nicotine Tob Res. 2016 Jan; 18(1):74-8. PMID: 25895948.
      View in: PubMed
    30. Hamilton DA, Mahoney MC, Novalen M, Chenoweth MJ, Heitjan DF, Lerman C, Tyndale RF, Hawk LW. Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. Nicotine Tob Res. 2015 Dec; 17(12):1505-9. PMID: 25732567.
      View in: PubMed
    31. Lerman C, Schnoll RA, Hawk LW, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, Tyndale RF. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015 Feb; 3(2):131-138. PMID: 25588294.
      View in: PubMed
    32. Loughead J, Wileyto EP, Ruparel K, Falcone M, Hopson R, Gur R, Lerman C. Working memory-related neural activity predicts future smoking relapse. Neuropsychopharmacology. 2015 May; 40(6):1311-20. PMID: 25469682.
      View in: PubMed
    33. Chenoweth MJ, Novalen M, Hawk LW, Schnoll RA, George TP, Cinciripini PM, Lerman C, Tyndale RF. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev. 2014 Sep; 23(9):1773-82. PMID: 25012994.
      View in: PubMed
    34. Lerman C, Gu H, Loughead J, Ruparel K, Yang Y, Stein EA. Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function. JAMA Psychiatry. 2014 May; 71(5):523-30. PMID: 24622915.
      View in: PubMed
    35. Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, Conti DV. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. Drug Alcohol Depend. 2014 May 01; 138:109-17. PMID: 24667010.
      View in: PubMed
    36. David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, Bergen AW, Swan GE, Benowitz NL, Tyndale RF, Conti DV, Brown RA, Lerman C, Niaura R. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction. 2013 Dec; 108(12):2202-11. PMID: 23941313.
      View in: PubMed
    37. Ashare RL, Wileyto EP, Ruparel K, Goelz PM, Hopson RD, Valdez JN, Gur RC, Loughead J, Lerman C. Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study. Drug Alcohol Depend. 2013 Dec 15; 133(3):852-6. PMID: 24095246.
      View in: PubMed
    38. Turner JR, Ray R, Lee B, Everett L, Xiang J, Jepson C, Kaestner KH, Lerman C, Blendy JA. Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. Mol Psychiatry. 2014 Jul; 19(7):801-10. PMID: 23999525.
      View in: PubMed
    39. Perkins KA, Lerman C, Karelitz JL, Jao NC, Chengappa KN, Sparks GM. Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. Addiction. 2013 Nov; 108(11):1962-8. PMID: 23773319.
      View in: PubMed
    40. Falcone M, Smith RM, Chenoweth MJ, Bhattacharjee AK, Kelsoe JR, Tyndale RF, Lerman C. Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls. Neuropsychopharmacology. 2013 Nov; 38(12):2327-37. PMID: 23793356.
      View in: PubMed
    41. Falcone M, Lerman C, Cappella JN, Sanborn P, Jepson C, Strasser AA. No untoward effects of smoking cues in anti-smoking public service announcements. Drug Alcohol Depend. 2013 Nov 01; 133(1):279-82. PMID: 23742844.
      View in: PubMed
    42. Perkins KA, Karelitz JL, Jao NC, Gur RC, Lerman C. Effects of bupropion on cognitive performance during initial tobacco abstinence. Drug Alcohol Depend. 2013 Nov 01; 133(1):283-6. PMID: 23726977.
      View in: PubMed
    43. Wang AL, Ruparel K, Loughead JW, Strasser AA, Blady SJ, Lynch KG, Romer D, Cappella JN, Lerman C, Langleben DD. Content matters: neuroimaging investigation of brain and behavioral impact of televised anti-tobacco public service announcements. J Neurosci. 2013 Apr 24; 33(17):7420-7. PMID: 23616548.
      View in: PubMed
    44. Falcone M, Wileyto EP, Ruparel K, Gerraty RT, LaPrate L, Detre JA, Gur R, Loughead J, Lerman C. Age-related differences in working memory deficits during nicotine withdrawal. Addict Biol. 2014 Sep; 19(5):907-17. PMID: 23496760.
      View in: PubMed
    45. Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, David SP, Stein EA, Uhl GR, Conti DV, Green C, Amur S. Biomarkers for smoking cessation. Clin Pharmacol Ther. 2013 Jun; 93(6):526-38. PMID: 23588313.
      View in: PubMed
    46. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, Liu J, Lee W, Edlund CK, Hall S, Kwok PY, Benowitz NL, Baker TB, Tyndale RF, Lerman C, Swan GE. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics. 2013 Feb; 23(2):94-103. PMID: 23249876.
      View in: PubMed
    47. Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, Tyndale RF. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):708-18. PMID: 23371292.
      View in: PubMed
    48. Ashare RL, Karlawish JH, Wileyto EP, Pinto A, Lerman C. APOE ?4, an Alzheimer's disease susceptibility allele, and smoking cessation. Pharmacogenomics J. 2013 Dec; 13(6):538-43. PMID: 23247396.
      View in: PubMed
    49. Bergen AW, Javitz HS, Su L, He Y, Conti DV, Benowitz NL, Tyndale RF, Lerman C, Swan GE. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. Nicotine Tob Res. 2013 Jul; 15(7):1190-200. PMID: 23212438.
      View in: PubMed
    50. Lee S, Cappella JN, Lerman C, Strasser AA. Effects of smoking cues and argument strength of antismoking advertisements on former smokers' self-efficacy, attitude, and intention to refrain from smoking. Nicotine Tob Res. 2013 Feb; 15(2):527-33. PMID: 22949578.
      View in: PubMed
    51. Lee W, Ray R, Bergen AW, Swan GE, Thomas P, Tyndale RF, Benowitz NL, Lerman C, Conti DV. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. Pharmacogenet Genomics. 2012 Jul; 22(7):551-4. PMID: 22495174.
      View in: PubMed
    52. Ashare RL, Ray R, Lerman C, Strasser AA. Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study. Drug Alcohol Depend. 2012 Nov 01; 126(1-2):263-7. PMID: 22595038.
      View in: PubMed
    53. Javitz HS, Lerman C, Swan GE. Comparative dynamics of four smoking withdrawal symptom scales. Addiction. 2012 Aug; 107(8):1501-11. PMID: 22321019.
      View in: PubMed
    54. Falcone M, Gold AB, Wileyto EP, Ray R, Ruparel K, Newberg A, Dubroff J, Logan J, Zubieta JK, Blendy JA, Lerman C. µ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Psychopharmacology (Berl). 2012 Aug; 222(4):701-8. PMID: 22389047.
      View in: PubMed
    55. Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology. 2012 Jun; 37(7):1683-8. PMID: 22373943.
      View in: PubMed
    56. Gold AB, Lerman C. Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet. 2012 Jan 31. PMID: 22290489.
      View in: PubMed
    57. Schnoll RA, Wileyto EP, Lerman C. Extended duration therapy with transdermal nicotine may attenuate weight gain following smoking cessation. Addict Behav. 2012 Apr; 37(4):565-8. PMID: 22244706.
      View in: PubMed
    58. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, Kaprio J, Lerman C, Park PW. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012 Feb; 37(3):641-50. PMID: 22048466.
      View in: PubMed
    59. Falcone M, Jepson C, Sanborn P, Cappella JN, Lerman C, Strasser AA. Association of BDNF and COMT genotypes with cognitive processing of anti-smoking PSAs. Genes Brain Behav. 2011 Nov; 10(8):862-7. PMID: 21883922.
      View in: PubMed
    60. Javitz HS, Swan GE, Lerman C. The dynamics of the urge-to-smoke following smoking cessation via pharmacotherapy. Addiction. 2011 Oct; 106(10):1835-45. PMID: 21561501.
      View in: PubMed
    61. Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, Tyndale RF, Benowitz NL, Lerman C, Conti DV. Gender-stratified gene and gene-treatment interactions in smoking cessation. Pharmacogenomics J. 2012 Dec; 12(6):521-32. PMID: 21808284.
      View in: PubMed
    62. Schnoll RA, Cappella J, Lerman C, Pinto A, Patterson F, Wileyto EP, Bigman C, Leone F. A novel recruitment message to increase enrollment into a smoking cessation treatment program: preliminary results from a randomized trial. Health Commun. 2011 Dec; 26(8):735-42. PMID: 21667366.
      View in: PubMed
    63. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A. 2011 May 31; 108(22):9268-73. PMID: 21576462.
      View in: PubMed
    64. Loughead J, Ray R, Wileyto EP, Ruparel K, O'Donnell GP, Senecal N, Siegel S, Gur RC, Lerman C. Brain activity and emotional processing in smokers treated with varenicline. Addict Biol. 2013 Jul; 18(4):732-8. PMID: 21507156.
      View in: PubMed
    65. Falcone M, Jepson C, Benowitz N, Bergen AW, Pinto A, Wileyto EP, Baldwin D, Tyndale RF, Lerman C, Ray R. Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Nicotine Tob Res. 2011 Jun; 13(6):498-503. PMID: 21385908.
      View in: PubMed
    66. Lee S, Cappella JN, Lerman C, Strasser AA. Smoking cues, argument strength, and perceived effectiveness of antismoking PSAs. Nicotine Tob Res. 2011 Apr; 13(4):282-90. PMID: 21330273.
      View in: PubMed
    67. Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, Tyndale RF, Lerman CE. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev. 2011 Feb; 20(2):234-8. PMID: 21212060.
      View in: PubMed
    68. Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KN, Jain A. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther. 2010 Jul; 88(1):109-14. PMID: 20485335.
      View in: PubMed
    69. Rudnick ND, Strasser AA, Phillips JM, Jepson C, Patterson F, Frey JM, Turetsky BI, Lerman C, Siegel SJ. Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. Nicotine Tob Res. 2010 Jun; 12(6):589-97. PMID: 20395358.
      View in: PubMed
    70. Wei J, Ma JZ, Payne TJ, Cui W, Ray R, Mitra N, Lerman C, Li MD. Replication and extension of association of choline acetyltransferase with nicotine dependence in European and African American smokers. Hum Genet. 2010 Jun; 127(6):691-8. PMID: 20383528.
      View in: PubMed
    71. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, Tyndale RF. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther. 2010 May; 87(5):553-7. PMID: 20336063.
      View in: PubMed
    72. Perkins KA, Mercincavage M, Fonte CA, Lerman C. Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology (Berl). 2010 May; 210(1):45-51. PMID: 20306175.
      View in: PubMed
    73. Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman C. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry. 2010 Apr 15; 67(8):715-21. PMID: 20207347.
      View in: PubMed
    74. Leader AE, Lerman C, Cappella JN. Nicotine vaccines: will smokers take a shot at quitting? Nicotine Tob Res. 2010 Apr; 12(4):390-7. PMID: 20185516.
      View in: PubMed
    75. Ray R, Mitra N, Baldwin D, Guo M, Patterson F, Heitjan DF, Jepson C, Wileyto EP, Wei J, Payne T, Ma JZ, Li MD, Lerman C. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology. 2010 May; 35(6):1374-82. PMID: 20147892.
      View in: PubMed
    76. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, Lerman C. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010 Feb 02; 152(3):144-51. PMID: 20124230.
      View in: PubMed
    77. Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL. Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2608-12. PMID: 19755656.
      View in: PubMed
    78. Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S, Frey J, Gur R, Lerman C. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend. 2010 Jan 01; 106(1):61-4. PMID: 19733449.
      View in: PubMed
    79. Baker TB, Cummings KM, Hatsukami DK, Johnson CA, Lerman C, Niaura R, O'Malley SS. Transdisciplinary Tobacco Use Research Centers: research achievements and future implications. Nicotine Tob Res. 2009 Oct; 11(10):1231-44. PMID: 19633277.
      View in: PubMed
    80. Thomas PD, Mi H, Swan GE, Lerman C, Benowitz N, Tyndale RF, Bergen AW, Conti DV. A systems biology network model for genetic association studies of nicotine addiction and treatment. Pharmacogenet Genomics. 2009 Jul; 19(7):538-51. PMID: 19525886.
      View in: PubMed
    81. Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, Tildesley E, Hops H, Tyndale RF, Benowitz NL, Lerman C, Swan GE. Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology. 2009 Sep; 34(10):2252-64. PMID: 19494806.
      View in: PubMed
    82. Newberg AB, Ray R, Scheuermann J, Wintering N, Saffer J, Schmitz A, Freifelder R, Karp J, Lerman C, Divgi C. Dosimetry of 11C-carfentanil, a micro-opioid receptor imaging agent. Nucl Med Commun. 2009 Apr; 30(4):314-8. PMID: 19242386.
      View in: PubMed
    83. Kang Y, Cappella JN, Strasser AA, Lerman C. The effect of smoking cues in antismoking advertisements on smoking urge and psychophysiological reactions. Nicotine Tob Res. 2009 Mar; 11(3):254-61. PMID: 19251767.
      View in: PubMed
    84. Perkins KA, Briski J, Fonte C, Scott J, Lerman C. Severity of tobacco abstinence symptoms varies by time of day. Nicotine Tob Res. 2009 Jan; 11(1):84-91. PMID: 19246445.
      View in: PubMed
    85. Stepanov I, Carmella SG, Han S, Pinto A, Strasser AA, Lerman C, Hecht SS. Evidence for endogenous formation of N'-nitrosonornicotine in some long-term nicotine patch users. Nicotine Tob Res. 2009 Jan; 11(1):99-105. PMID: 19246447.
      View in: PubMed
    86. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet. 2009; 23(3):252-61. PMID: 19169923.
      View in: PubMed
    87. Ray R, Schnoll RA, Lerman C. Nicotine dependence: biology, behavior, and treatment. Annu Rev Med. 2009; 60:247-60. PMID: 19630572.
      View in: PubMed
    88. Loughead J, Wileyto EP, Valdez JN, Sanborn P, Tang K, Strasser AA, Ruparel K, Ray R, Gur RC, Lerman C. Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol Psychiatry. 2009 Aug; 14(8):820-6. PMID: 19065145.
      View in: PubMed
    89. Furberg H, Lichtenstein P, Pedersen NL, Thornton L, Bulik CM, Lerman C, Sullivan PF. The STAGE cohort: a prospective study of tobacco use among Swedish twins. Nicotine Tob Res. 2008 Dec; 10(12):1727-35. PMID: 18988069.
      View in: PubMed
    90. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009 Mar; 92(1):6-11. PMID: 19000709.
      View in: PubMed
    91. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009 Jan 15; 65(2):144-9. PMID: 18842256.
      View in: PubMed
    92. Heitjan DF, Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C. Identification of pharmacogenetic markers in smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 05; 147B(6):712-9. PMID: 18165968.
      View in: PubMed
    93. Perkins KA, Coddington SB, Karelitz JL, Jetton C, Scott JA, Wilson AS, Lerman C. Variability in initial nicotine sensitivity due to sex, history of other drug use, and parental smoking. Drug Alcohol Depend. 2009 Jan 01; 99(1-3):47-57. PMID: 18775605.
      View in: PubMed
    94. Perkins KA, Lerman C, Grottenthaler A, Ciccocioppo MM, Milanak M, Conklin CA, Bergen AW, Benowitz NL. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol. 2008 Sep; 19(5-6):641-9. PMID: 18690118.
      View in: PubMed
    95. Perkins KA, Lerman C, Coddington S, Jetton C, Karelitz JL, Wilson A, Jennings JR, Ferrell R, Bergen AW, Benowitz NL. Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers. Behav Pharmacol. 2008 Sep; 19(5-6):630-40. PMID: 18690117.
      View in: PubMed
    96. Furberg H, Lichtenstein P, Pedersen NL, Bulik CM, Lerman C, Sullivan PF. Snus use and other correlates of smoking cessation in the Swedish Twin Registry. Psychol Med. 2008 Sep; 38(9):1299-308. PMID: 18680625.
      View in: PubMed
    97. Perkins KA, Lerman C, Coddington S, Karelitz JL. Association of retrospective early smoking experiences with prospective sensitivity to nicotine via nasal spray in nonsmokers. Nicotine Tob Res. 2008 Aug; 10(8):1335-45. PMID: 18686181.
      View in: PubMed
    98. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, Bergen AW, Swan GE, Tyndale RF, Benowitz NL, Lerman C. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet. 2008 Sep 15; 17(18):2834-48. PMID: 18593715.
      View in: PubMed
    99. David SP, Johnstone EC, Murphy MF, Aveyard P, Guo B, Lerman C, Munafò MR. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend. 2008 Nov 01; 98(1-2):77-85. PMID: 18562131.
      View in: PubMed
    100. Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, Perkins KA, Dackis C, Heitjan DF, Berrettini W, Lerman C. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend. 2008 Nov 01; 98(1-2):86-93. PMID: 18541389.
      View in: PubMed
    101. Ray R, Loughead J, Wang Z, Detre J, Yang E, Gur R, Lerman C. Neuroimaging, genetics and the treatment of nicotine addiction. Behav Brain Res. 2008 Nov 21; 193(2):159-69. PMID: 18599130.
      View in: PubMed
    102. Shields AE, Levy DE, Blumenthal D, Currivan D, McGinn-Shapiro M, Weiss KB, Yucel R, Lerman C. Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. Nicotine Tob Res. 2008 Jun; 10(6):1037-45. PMID: 18584467.
      View in: PubMed
    103. Piper ME, McCarthy DE, Bolt DM, Smith SS, Lerman C, Benowitz N, Fiore MC, Baker TB. Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). Nicotine Tob Res. 2008 Jun; 10(6):1009-20. PMID: 18584464.
      View in: PubMed
    104. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry. 2008 Jun; 65(6):683-93. PMID: 18519826.
      View in: PubMed
    105. Ray R, Rukstalis M, Jepson C, Strasser A, Patterson F, Lynch K, Lerman C. Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence. J Psychopharmacol. 2009 Mar; 23(2):168-76. PMID: 18515446.
      View in: PubMed
    106. Wang Z, Ray R, Faith M, Tang K, Wileyto EP, Detre JA, Lerman C. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neurosci Lett. 2008 Jun 27; 438(3):275-80. PMID: 18499348.
      View in: PubMed
    107. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, Hawk LW, Tyndale RF, Benowitz N, Lerman C. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther. 2008 Sep; 84(3):320-5. PMID: 18388868.
      View in: PubMed
    108. Penning TM, Lerman C. Genomics of smoking exposure and cessation: lessons for cancer prevention and treatment. Cancer Prev Res (Phila). 2008 Jul; 1(2):80-3. PMID: 19138939.
      View in: PubMed
    109. Perkins KA, Lerman C, Stitzer M, Fonte CA, Briski JL, Scott JA, Chengappa KN. Development of procedures for early screening of smoking cessation medications in humans. Clin Pharmacol Ther. 2008 Aug; 84(2):216-21. PMID: 18388880.
      View in: PubMed
    110. Heitjan DF, Asch DA, Ray R, Rukstalis M, Patterson F, Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J. 2008 Dec; 8(6):391-9. PMID: 18347612.
      View in: PubMed
    111. Patterson F, Kerrin K, Wileyto EP, Lerman C. Increase in anger symptoms after smoking cessation predicts relapse. Drug Alcohol Depend. 2008 May 01; 95(1-2):173-6. PMID: 18328642.
      View in: PubMed
    112. Wang Z, Faith M, Patterson F, Tang K, Kerrin K, Wileyto EP, Detre JA, Lerman C. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. J Neurosci. 2007 Dec 19; 27(51):14035-40. PMID: 18094242.
      View in: PubMed
    113. David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, Evins AE, Shields PG, Lerman C, Niaura R. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res. 2007 12; 9(12):1251-7. PMID: 18058343.
      View in: PubMed
    114. Lerman CE, Schnoll RA, Munafò MR. Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med. 2007 Dec; 33(6 Suppl):S398-405. PMID: 18021915.
      View in: PubMed
    115. Phillips JM, Siegel SJ, Shields AE, Patterson F, Gould TJ, Strasser AA, Ray R, Pinto A, Audrain-McGovern J, Rukstalis M, Perkins KA, Blendy JA, Lerman C. Translating basic science to improve pharmacotherapy for nicotine dependence. Nicotine Tob Res. 2007 Nov; 9 Suppl 4:S583-98. PMID: 18067034.
      View in: PubMed
    116. Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine Tob Res. 2007 Nov; 9(11):1237-41. PMID: 17978999.
      View in: PubMed
    117. Schnoll RA, Johnson TA, Lerman C. Genetics and smoking behavior. Curr Psychiatry Rep. 2007 Oct; 9(5):349-57. PMID: 17915073.
      View in: PubMed
    118. Schnoll RA, Patterson F, Lerman C. Treating tobacco dependence in women. J Womens Health (Larchmt). 2007 Oct; 16(8):1211-8. PMID: 17937574.
      View in: PubMed
    119. Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL, Stitzel J, Bryan A, McGeary J, Haughey HM. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry. 2007 Sep; 64(9):1078-86. PMID: 17768273.
      View in: PubMed
    120. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, Corrigall WA. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov. 2007 Sep; 6(9):746-62. PMID: 17690709.
      View in: PubMed
    121. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007 Aug; 9(8):821-33. PMID: 17654295.
      View in: PubMed
    122. Ray R, Jepson C, Wileyto P, Patterson F, Strasser AA, Rukstalis M, Perkins K, Blendy J, Lerman C. CREB1 haplotypes and the relative reinforcing value of nicotine. Mol Psychiatry. 2007 Jul; 12(7):615-7. PMID: 17592483.
      View in: PubMed
    123. Schnoll RA, Epstein L, Audrain J, Niaura R, Hawk L, Shields PG, Lerman C, Wileyto EP. Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. J Subst Abuse Treat. 2008 Mar; 34(2):234-41. PMID: 17600649.
      View in: PubMed
    124. Leventhal AM, Waters AJ, Boyd S, Moolchan ET, Heishman SJ, Lerman C, Pickworth WB. Associations between Cloninger's temperament dimensions and acute tobacco withdrawal. Addict Behav. 2007 Dec; 32(12):2976-89. PMID: 17624682.
      View in: PubMed
    125. Waters AJ, Heishman SJ, Lerman C, Pickworth W. Enhanced identification of smoking-related words during the attentional blink in smokers. Addict Behav. 2007 Dec; 32(12):3077-82. PMID: 17616446.
      View in: PubMed
    126. Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1312-4. PMID: 17548706.
      View in: PubMed
    127. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res. 2007 Apr; 9(4):511-8. PMID: 17454707.
      View in: PubMed
    128. Leventhal AM, Waters AJ, Boyd S, Moolchan ET, Lerman C, Pickworth WB. Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Exp Clin Psychopharmacol. 2007 Feb; 15(1):21-36. PMID: 17295582.
      View in: PubMed
    129. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry. 2007 Sep 15; 62(6):635-41. PMID: 17223085.
      View in: PubMed
    130. Ray R, Schnoll RA, Lerman C. Pharmacogenetics and smoking cessation with nicotine replacement therapy. CNS Drugs. 2007; 21(7):525-33. PMID: 17579497.
      View in: PubMed
    131. Munafò M, Lerman C. Can pharmacogenetics help smokers quit? Pharmacogenomics. 2006 Dec; 7(8):1137-40. PMID: 17184199.
      View in: PubMed
    132. Hu J, Redden DT, Berrettini WH, Shields PG, Restine SL, Pinto A, Lerman C, Allison DB. No evidence for a major role of polymorphisms during bupropion treatment. Obesity (Silver Spring). 2006 Nov; 14(11):1863-7. PMID: 17135598.
      View in: PubMed
    133. Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, Lynch KG, O'Malley S, Berrettini WH, Lerman C. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl). 2006 Oct; 188(3):355-63. PMID: 16960700.
      View in: PubMed
    134. Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs. 2006 Sep; 11(3):429-44. PMID: 16939383.
      View in: PubMed
    135. Strasser AA, Lerman C, Sanborn PM, Pickworth WB, Feldman EA. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend. 2007 Jan 12; 86(2-3):294-300. PMID: 16930853.
      View in: PubMed
    136. Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P, Niaura R, Lerman C. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry. 2007 Jan 01; 61(1):111-8. PMID: 16876132.
      View in: PubMed
    137. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006 Jun; 79(6):600-8. PMID: 16765148.
      View in: PubMed
    138. Lerman C. Helping smokers quit through pharmacogenetics. LDI Issue Brief. 2006 May-Jun; 11(6):1-4. PMID: 16827222.
      View in: PubMed
    139. Dahl JP, Jepson C, Levenson R, Wileyto EP, Patterson F, Berrettini WH, Lerman C. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J. 2006 May-Jun; 6(3):194-9. PMID: 16402081.
      View in: PubMed
    140. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry. 2006 Apr; 11(4):400-9. PMID: 16402128.
      View in: PubMed
    141. Shadel WG, Lerman C, Cappella J, Strasser AA, Pinto A, Hornik R. Evaluating smokers' reactions to advertising for new lower nicotine quest cigarettes. Psychol Addict Behav. 2006 Mar; 20(1):80-4. PMID: 16536669.
      View in: PubMed
    142. Munafò MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev. 2006 Feb; 15(2):398-400. PMID: 16492936.
      View in: PubMed
    143. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology. 2006 Jan; 31(1):231-42. PMID: 16123753.
      View in: PubMed
    144. Furberg H, Bulik CM, Lerman C, Lichtenstein P, Pedersen NL, Sullivan PF. Is Swedish snus associated with smoking initiation or smoking cessation? Tob Control. 2005 Dec; 14(6):422-4. PMID: 16319367.
      View in: PubMed
    145. Perkins KA, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl). 2006 Mar; 184(3-4):628-36. PMID: 16163529.
      View in: PubMed
    146. Schnoll RA, Rothman RL, Wielt DB, Lerman C, Pedri H, Wang H, Babb J, Miller SM, Movsas B, Sherman E, Ridge JA, Unger M, Langer C, Goldberg M, Scott W, Cheng J. A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. Ann Behav Med. 2005 Aug; 30(1):1-11. PMID: 16097900.
      View in: PubMed
    147. Berrettini WH, Lerman CE. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry. 2005 Aug; 162(8):1441-51. PMID: 16055765.
      View in: PubMed
    148. Munafò MR, Lerman C, Niaura R, Shields AE, Swan GE. Smoking cessation treatment: pharmacogenetic assessment. Curr Opin Mol Ther. 2005 Jun; 7(3):202-8. PMID: 15977416.
      View in: PubMed
    149. Rukstalis M, Jepson C, Patterson F, Lerman C. Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J Subst Abuse Treat. 2005 Jun; 28(4):297-304. PMID: 15925263.
      View in: PubMed
    150. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics. 2005 Jun; 15(6):393-8. PMID: 15900212.
      View in: PubMed
    151. Wileyto EP, Patterson F, Niaura R, Epstein LH, Brown RA, Audrain-McGovern J, Hawk LW, Lerman C. Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine Tob Res. 2005 Apr; 7(2):257-68. PMID: 16036283.
      View in: PubMed
    152. Shields AE, Blumenthal D, Weiss KB, Comstock CB, Currivan D, Lerman C. Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J Gen Intern Med. 2005 Feb; 20(2):131-8. PMID: 15836545.
      View in: PubMed
    153. Rukstalis M, Jepson C, Strasser A, Lynch KG, Perkins K, Patterson F, Lerman C. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berl). 2005 Jun; 180(1):41-8. PMID: 15682300.
      View in: PubMed
    154. Lerman C, Patterson F, Berrettini W. Treating tobacco dependence: state of the science and new directions. J Clin Oncol. 2005 Jan 10; 23(2):311-23. PMID: 15637394.
      View in: PubMed
    155. Strasser AA, Kaufmann V, Jepson C, Perkins KA, Pickworth WB, Wileyto EP, Rukstalis M, Audrain-McGovern J, Lerman C. Effects of different nicotine replacement therapies on postcessation psychological responses. Addict Behav. 2005 Jan; 30(1):9-17. PMID: 15561445.
      View in: PubMed
    156. Lerman C, Niaura R, Collins BN, Wileyto P, Audrain-McGovern J, Pinto A, Hawk L, Epstein LH. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav. 2004 Dec; 18(4):362-6. PMID: 15631608.
      View in: PubMed
    157. Strasser AA, Pickworth WB, Patterson F, Lerman C. Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2004 Nov; 13(11 Pt 1):1800-4. PMID: 15533910.
      View in: PubMed
    158. Shields A, Lerman C, Sullivan P. Translating emerging research on the genetics of smoking into clinical practice: ethical and social considerations. Nicotine Tob Res. 2004 Aug; 6(4):675-88. PMID: 15370164.
      View in: PubMed
    159. Jaroni JL, Wright SM, Lerman C, Epstein LH. Relationship between education and delay discounting in smokers. Addict Behav. 2004 Aug; 29(6):1171-5. PMID: 15236819.
      View in: PubMed
    160. Epstein LH, Wright SM, Paluch RA, Leddy JJ, Hawk LW, Jaroni JL, Saad FG, Crystal-Mansour S, Shields PG, Lerman C. Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. Am J Clin Nutr. 2004 Jul; 80(1):82-8. PMID: 15213032.
      View in: PubMed
    161. Audrain-McGovern J, Lerman C, Wileyto EP, Rodriguez D, Shields PG. Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry. 2004 Jul; 161(7):1224-30. PMID: 15229055.
      View in: PubMed
    162. Perkins KA, Lerman C, Keenan J, Fonte C, Coddington S. Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers. Nicotine Tob Res. 2004 Jun; 6(3):501-7. PMID: 15203784.
      View in: PubMed
    163. Epstein LH, Wright SM, Paluch RA, Leddy J, Hawk LW, Jaroni JL, Saad FG, Crystal-Mansour S, Lerman C. Food hedonics and reinforcement as determinants of laboratory food intake in smokers. Physiol Behav. 2004 May; 81(3):511-7. PMID: 15135024.
      View in: PubMed
    164. Lerman C, Berrettini W, Pinto A, Patterson F, Crystal-Mansour S, Wileyto EP, Restine SL, Leonard DG, Shields PG, Epstein LH. Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl). 2004 Aug; 174(4):571-7. PMID: 15138759.
      View in: PubMed
    165. Wileyto P, Patterson F, Niaura R, Epstein L, Brown R, Audrain-McGovern J, Hawk L, Lerman C, Patterson F. Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine Tob Res. 2004 Apr; 6(2):357-66. PMID: 15203809.
      View in: PubMed
    166. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, Benowitz N. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med. 2004 Mar 16; 140(6):426-33. PMID: 15023708.
      View in: PubMed
    167. Schnoll RA, Rothman RL, Lerman C, Miller SM, Newman H, Movsas B, Sherman E, Ridge JA, Unger M, Langer C, Goldberg M, Scott W, Cheng J. Comparing cancer patients who enroll in a smoking cessation program at a comprehensive cancer center with those who decline enrollment. Head Neck. 2004 Mar; 26(3):278-86. PMID: 14999804.
      View in: PubMed
    168. Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V, Pinto A, Hawk L, Niaura R, Epstein LH, Lerman C. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res. 2004 Feb; 6(1):27-37. PMID: 14982685.
      View in: PubMed
    169. Lessov CN, Swan GE, Ring HZ, Khroyan TV, Lerman C. Genetics and drug use as a complex phenotype. Subst Use Misuse. 2004; 39(10-12):1515-69. PMID: 15587945.
      View in: PubMed
    170. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 2004; 4(3):184-92. PMID: 15007373.
      View in: PubMed
    171. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenomics J. 2004; 4(2):102-9. PMID: 14732864.
      View in: PubMed
    172. Baker TB, Hatsukami DK, Lerman C, O'Malley SS, Shields AE, Fiore MC. Transdisciplinary science applied to the evaluation of treatments for tobacco use. Nicotine Tob Res. 2003 Dec; 5 Suppl 1:S89-99. PMID: 14668089.
      View in: PubMed
    173. Shenassa ED, McCaffery JM, Swan GE, Khroyan TV, Shakib S, Lerman C, Lyons M, Mouttapa M, Niaura RS, Buka SL, Leslie F, Santangelo SL. Intergenerational transmission of tobacco use and dependence: a transdisciplinary perspective. Nicotine Tob Res. 2003 Dec; 5 Suppl 1:S55-69. PMID: 14668087.
      View in: PubMed
    174. Kaufmann V, Jepson C, Rukstalis M, Perkins K, Audrain-McGovern J, Lerman C. Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology (Berl). 2004 Mar; 172(3):271-6. PMID: 14647969.
      View in: PubMed
    175. Patterson F, Jepson C, Kaufmann V, Rukstalis M, Audrain-McGovern J, Kucharski S, Lerman C. Predictors of attendance in a randomized clinical trial of nicotine replacement therapy with behavioral counseling. Drug Alcohol Depend. 2003 Nov 24; 72(2):123-31. PMID: 14636967.
      View in: PubMed
    176. Kaufmann V, Lerman C. Genes, smoking, and treatment response. Am J Health Syst Pharm. 2003 Sep 15; 60(18):1911. PMID: 14521049.
      View in: PubMed
    177. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH, Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 2003 Sep; 22(5):541-8. PMID: 14570538.
      View in: PubMed
    178. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003 Jul; 45(1):122-32. PMID: 12814665.
      View in: PubMed
    179. Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, Kucharski S, Lerman C. Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev. 2003 May; 12(5):468-71. PMID: 12750245.
      View in: PubMed
    180. Lerman C, Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genet B Neuropsychiatr Genet. 2003 Apr 01; 118B(1):48-54. PMID: 12627466.
      View in: PubMed
    181. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 2002 Nov; 12(8):627-34. PMID: 12439223.
      View in: PubMed
    182. Lerman C, Niaura R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene. 2002 Oct 21; 21(48):7412-20. PMID: 12379882.
      View in: PubMed
    183. Lerman C, Swan GE. Non-replication of genetic association studies: is DAT all, folks? Nicotine Tob Res. 2002 Aug; 4(3):247-9. PMID: 12215232.
      View in: PubMed
    184. Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2002 Jul 01; 67(2):219-23. PMID: 12095672.
      View in: PubMed
    185. Lerman C, Audrain J, Tercyak K, Hawk LW, Bush A, Crystal-Mansour S, Rose C, Niaura R, Epstein LH. Attention-Deficit Hyperactivity Disorder (ADHD) symptoms and smoking patterns among participants in a smoking-cessation program. Nicotine Tob Res. 2001 Nov; 3(4):353-9. PMID: 11694203.
      View in: PubMed
    186. Caporaso NE, Lerman C, Audrain J, Boyd NR, Main D, Issaq HJ, Utermahlan B, Falk RT, Shields P. Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):261-3. PMID: 11303596.
      View in: PubMed
    187. Lerman C, Caporaso NE, Audrain J, Main D, Boyd NR, Shields PG. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol Psychiatry. 2000 Mar; 5(2):189-92. PMID: 10822347.
      View in: PubMed
    188. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B, Boyd NR, Shields PG. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol. 1999 Jan; 18(1):14-20. PMID: 9925041.
      View in: PubMed
    189. Shields PG, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR, Caporaso NE. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 1998 Jun; 7(6):453-8. PMID: 9641486.
      View in: PubMed
    190. Lerman C, Shields PG, Audrain J, Main D, Cobb B, Boyd NR, Caporaso N. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prev. 1998 Mar; 7(3):253-5. PMID: 9521442.
      View in: PubMed
    191. Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, Shields PG. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol. 1998 Jan; 17(1):56-62. PMID: 9459071.
      View in: PubMed
    192. Audrain J, Boyd NR, Roth J, Main D, Caporaso NF, Lerman C. Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. Addict Behav. 1997 Nov-Dec; 22(6):741-51. PMID: 9426791.
      View in: PubMed
    193. Audrain J, Gomez-Caminero A, Robertson AR, Boyd R, Orleans CT, Lerman C. Gender and ethnic differences in readiness to change smoking behavior. Womens Health. 1997; 3(2):139-50. PMID: 9332155.
      View in: PubMed
    194. Lerman C, Gold K, Audrain J, Lin TH, Boyd NR, Orleans CT, Wilfond B, Louben G, Caporaso N. Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. Health Psychol. 1997 Jan; 16(1):87-99. PMID: 9028818.
      View in: PubMed
    195. Lerman C, Audrain J, Orleans CT, Boyd R, Gold K, Main D, Caporaso N. Investigation of mechanisms linking depressed mood to nicotine dependence. Addict Behav. 1996 Jan-Feb; 21(1):9-19. PMID: 8729703.
      View in: PubMed
    196. Lerman C, Orleans CT, Engstrom PF. Biological markers in smoking cessation treatment. Semin Oncol. 1993 Aug; 20(4):359-67. PMID: 8342065.
      View in: PubMed